

Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment

Information for the public

Published: 15 May 2025

www.nice.org.uk

Capivasertib (Truqap) plus fulvestrant is available on the NHS. It is a possible treatment for hormone receptor-positive HER2-negative breast cancer in adults that:

- is locally advanced (has spread to nearby tissues) or metastatic (has spread to other parts of the body)
- has 1 or more PIK3CA, AKT1 or PTEN gene alterations
- has recurred (come back) or progressed (got worse) after a CKD 4 and 6 inhibitor plus an aromatase inhibitor (a type of endocrine treatment).

If you are not eligible for capivasertib plus fulvestrant but are already having it, you should be able to continue until you and your healthcare professional decide when best to stop.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. See [our webpage on making decisions about your care](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

The [NHS webpages on breast cancer in women](#) and [breast cancer in men](#) may be a good place to find out more.

These organisations can give you advice and support:

- [Breast Cancer Now](#), 0808 800 6000
- [METUP UK](#), join-us@metupuk.org.uk
- [Make 2nds Count](#), 0131 357 4811
- [Cancer Research UK](#), 0808 800 4040
- [Macmillan Cancer Support](#), 0800 808 0000

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-7011-7